Cognome - Nome |
FILIPPI Luca |
Posizione |
Professore Associato |
Telefono |
+39 06 2090 2411 |
S.S.D. |
MED/36 – Medicina Nucleare |
S.C. |
06/I1 - DIAGNOSTICA PER IMMAGINI, RADIOTERAPIA E NEURORADIOLOGIA |
e-mail |
|
Interessi di Ricerca |
● Applications of AI and radiomics in nuclear medicine ● "Multi-tracer" imaging in prostate cancer ● Metabolic imaging in skin tumors ● Theranostic |
Luca Filippi è Professore Associato di Medicina Nucleare (MED/36) presso il Dipartimento di Biomedicina e Prevenzione. Le linee di ricerca di Luca Filippi sono state sviluppate prevalentemente nell'ambito dell’imaging molecolare e metabolico PET/SPECT e della “targeted therapy” nella prospettiva di un sinergismo tra le discipline. In particolare, negli ultimi anni, l’attività di ricerca si è concentrata prevalentemente sulle seguenti tematiche: 1) imaging multi-tracciante (18F-colina/18F-FACBC/PMSA-ligandi) per lo studio del carcinoma della prostata, sia per la diagnosi della recidiva biochimica che per la stratificazione prognostica ai fini di trattamenti sistemici o radioterapici mirati, con particolare attenzione alle applicazioni teranostiche e alla implementazione delle nuove tecnologie (PET digitale, PET “long-axial fied of view”); 2) applicazioni della PET/CT con 18F-FDG nei tumori cutanei sottoposti a trattamenti con inibitori del check-point immunitario o a “molecularly targeted therapy”; 3) uso delle microsfere radiomarcate con 90Y per il trattamento dei tumori epatici primitivi e secondari, con riferimento alla stratificazione prognostica e alla dosimetria “voxel-based”. Più recentemente, l’attività scientifica di Luca Filippi è andata a incentrarsi sulle applicazioni della intelligenza artificiale e della “radiomica”, la disciplina basata sulla estrazione di dati quantitativi e riproducibili dalle immagini mediche, per la costruzione di modelli predittivi in ambito oncologico. In tale contesto, sono state attivate collaborazioni a livello sia nazionale, come Vice-segretario del Gruppo di Studio AI/radiomica della Associazione Italiana di Medicina Nucleare (AIMN), che internazionale. Membro del comitato editoriale di numerose riviste internazionali ed Editor-in-Chief della rivista “Expert Review of Medical Devices” (Impact factor: 2.9). Vincitore di premi nazionali e internazionali, è Delegato per la Regione Lazio della Associazione Italiana di Medicina Nucleare. Svolge attività di docenza in ambito accademico e societario, come promotore di attività mirate al coinvolgimento dei giovani nelle discipline dell’imaging ibrido, della teranostica e della radiomica. Come si può ricavare dai dati SCOPUS, Luca Filippi è autore di oltre 177 pubblicazioni scientifiche indicizzate su SCOPUS, con un h-index pari a 29.
ISTRUZIONE E FORMAZIONE
● Laurea in Medicina e Chirurgia (Università degli Studi di Roma “La Sapienza”, 2001)
● Specializzazione in Medicina Nucleare (Università degli Studi di Roma “La Sapienza”, 2005)
● Corso Professionalizzante in “Nanotechnology and Nanomedicine” (University of Athens, Greece, 2020)
● Diploma in “Change Management and Digital Innovation” (Politecnico di Milano, 2021)
PUBBLICAZIONI SCIENTIFICHE (selezione)
● Filippi L, Schillaci O. Interim PET/CT with [68Ga]Ga-DOTA-peptides in NET prognostication: is Δ-radiomics the next frontier? Eur Radiol. 2024 Oct 18. doi: 10.1007/s00330-024-11117-4 (https://pubmed.ncbi.nlm.nih.gov/39436412/)
● Filippi L, Ferrari C, Rubini G. Theranostic strategies in sarcoma: preliminary clinical evidence. Expert Opin Investig Drugs. 2024 Oct 9:1-9. doi: 10.1080/13543784.2024.2414119 (https://pubmed.ncbi.nlm.nih.gov/39367699/)
● Filippi L, Urso L, Ferrari C, et al. The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective. Eur J Nucl Med Mol Imaging. 2024 Aug 7. doi: 10.1007/s00259-024-06866-9. (https://pubmed.ncbi.nlm.nih.gov/39110196/)
● Filippi L, Urso L, Frantellizzi V, et al. Molecular imaging of PARP in cancer: state-of-the-art. Expert Rev Mol Diagn. 2023 Jul-Dec;23(12):1167-1174. doi: 10.1080/14737159.2023.2287503 (https://pubmed.ncbi.nlm.nih.gov/38009232/)
● Filippi L, Proietti I, Petrozza V, et al. The Prognostic Role of [18F]FDG PET/CT in Patients with Advanced Cutaneous Squamous Cell Carcinoma Submitted to Cemiplimab Immunotherapy: A Single-Center Retrospective Study. Cancer Biother Radiopharm. 2024 Feb;39(1):46-54. doi: 10.1089/cbr.2023.0110 (https://pubmed.ncbi.nlm.nih.gov/37883658/)
Link SCOPUS profile: https://www.scopus.com/authid/detail.uri?authorId=5719687785
Family Name- Name |
FILIPPI Luca |
Position |
Associate Professor |
Office |
+39 06 2090 2411 |
S.S.D. |
MED/36 – Medicina Nucleare |
S.C. |
06/I1 - DIAGNOSTICA PER IMMAGINI, RADIOTERAPIA E NEURORADIOLOGIA |
e-mail |
|
Research Interests |
● Applications of AI and radiomics in nuclear medicine ● "Multi-tracer" imaging in prostate cancer ● Metabolic imaging in skin tumors ● Theranostic |
ACADEMIC EXPERIENCE
Luca Filippi is an Associate Professor of Nuclear Medicine (MED/36) at the Department of Biomedicine and Prevention. His research has primarily focused on molecular and metabolic imaging, specifically PET/SPECT, and on 'targeted therapy,' emphasizing synergies between disciplines. In recent years, his research activities have been primarily directed towards the following areas: 1) Multi-tracer imaging (18F-choline/18F-FACBC/PMSA-ligands) for the study of prostate cancer, aimed at diagnosing biochemical recurrence and prognostic stratification to guide systemic or targeted radiotherapy treatments, with particular attention to theranostic applications and the implementation of new technologies (digital PET, long-axial field of view PET); 2) Applications of 18F-FDG PET/CT in skin cancers treated with immune checkpoint inhibitors or molecularly targeted therapies; 2)Use of 90Y-labeled microspheres for the treatment of primary and secondary liver cancers, focusing on prognostic stratification and voxel-based dosimetry. More recently, Luca Filippi’s scientific work has concentrated on applications of artificial intelligence and 'radiomics,' a field dedicated to extracting reproducible quantitative data from medical images to develop predictive models in oncology. In this context, he has established both national collaborations, serving as Vice-Secretary of the AI/Radiomics Study Group of the Italian Association of Nuclear Medicine (AIMN), and international ones. He serves on the editorial board of numerous international journals and is Editor-in-Chief of 'Expert Review of Medical Devices' (Impact factor: 2.9). A recipient of national and international awards, he represents the Lazio Region in the Italian Association of Nuclear Medicine. His teaching activities extend across academia and professional societies, promoting initiatives to engage young professionals in hybrid imaging, theranostics, and radiomics. According to SCOPUS, Luca Filippi is the author of over 177 peer-reviewed publications indexed in SCOPUS, with an h-index of 29.
EDUCATION
● Degree in Medicine and Surgery (University of Rome “La Sapienza,” 2001)
● Specialization in Nuclear Medicine (University of Rome “La Sapienza,” 2005)
● Professional Course in “Nanotechnology and Nanomedicine” (University of Athens, Greece, 2020)
● Diploma in “Change Management and Digital Innovation” (Politecnico di Milano, 2021)
SCIENTIFIC PUBLICATIONS (selection)
● Filippi L, Schillaci O. Interim PET/CT with [68Ga]Ga-DOTA-peptides in NET prognostication: is Δ-radiomics the next frontier? Eur Radiol. 2024 Oct 18. doi: 10.1007/s00330-024-11117-4 (https://pubmed.ncbi.nlm.nih.gov/39436412/)
● Filippi L, Ferrari C, Rubini G. Theranostic strategies in sarcoma: preliminary clinical evidence. Expert Opin Investig Drugs. 2024 Oct 9:1-9. doi: 10.1080/13543784.2024.2414119 (https://pubmed.ncbi.nlm.nih.gov/39367699/)
● Filippi L, Urso L, Ferrari C, et al. The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective. Eur J Nucl Med Mol Imaging. 2024 Aug 7. doi: 10.1007/s00259-024-06866-9. (https://pubmed.ncbi.nlm.nih.gov/39110196/)
● Filippi L, Urso L, Frantellizzi V, et al. Molecular imaging of PARP in cancer: state-of-the-art. Expert Rev Mol Diagn. 2023 Jul-Dec;23(12):1167-1174. doi: 10.1080/14737159.2023.2287503 (https://pubmed.ncbi.nlm.nih.gov/38009232/)
● Filippi L, Proietti I, Petrozza V, et al. The Prognostic Role of [18F]FDG PET/CT in Patients with Advanced Cutaneous Squamous Cell Carcinoma Submitted to Cemiplimab Immunotherapy: A Single-Center Retrospective Study. Cancer Biother Radiopharm. 2024 Feb;39(1):46-54. doi: 10.1089/cbr.2023.0110 (https://pubmed.ncbi.nlm.nih.gov/37883658/)
Link SCOPUS profile: https://www.scopus.com/authid/detail.uri?authorId=571968778
Luca Filippi is an Associate Professor of Nuclear Medicine (MED/36) at the Department of Biomedicine and Prevention. His research has primarily focused on molecular and metabolic imaging, specifically PET/SPECT, and on 'targeted therapy,' emphasizing synergies between disciplines. In recent years, his research activities have been primarily directed towards the following areas: 1) Multi-tracer imaging (18F-choline/18F-FACBC/PMSA-ligands) for the study of prostate cancer, aimed at diagnosing biochemical recurrence and prognostic stratification to guide systemic or targeted radiotherapy treatments, with particular attention to theranostic applications and the implementation of new technologies (digital PET, long-axial field of view PET); 2) Applications of 18F-FDG PET/CT in skin cancers treated with immune checkpoint inhibitors or molecularly targeted therapies; 2)Use of 90Y-labeled microspheres for the treatment of primary and secondary liver cancers, focusing on prognostic stratification and voxel-based dosimetry. More recently, Luca Filippi’s scientific work has concentrated on applications of artificial intelligence and 'radiomics,' a field dedicated to extracting reproducible quantitative data from medical images to develop predictive models in oncology. In this context, he has established both national collaborations, serving as Vice-Secretary of the AI/Radiomics Study Group of the Italian Association of Nuclear Medicine (AIMN), and international ones. He serves on the editorial board of numerous international journals and is Editor-in-Chief of 'Expert Review of Medical Devices' (Impact factor: 2.9). A recipient of national and international awards, he represents the Lazio Region in the Italian Association of Nuclear Medicine. His teaching activities extend across academia and professional societies, promoting initiatives to engage young professionals in hybrid imaging, theranostics, and radiomics. According to SCOPUS, Luca Filippi is the author of over 177 peer-reviewed publications indexed in SCOPUS, with an h-index of 29.
EDUCATION
● Degree in Medicine and Surgery (University of Rome “La Sapienza,” 2001)
● Specialization in Nuclear Medicine (University of Rome “La Sapienza,” 2005)
● Professional Course in “Nanotechnology and Nanomedicine” (University of Athens, Greece, 2020)
● Diploma in “Change Management and Digital Innovation” (Politecnico di Milano, 2021)
SCIENTIFIC PUBLICATIONS (selection)
● Filippi L, Schillaci O. Interim PET/CT with [68Ga]Ga-DOTA-peptides in NET prognostication: is Δ-radiomics the next frontier? Eur Radiol. 2024 Oct 18. doi: 10.1007/s00330-024-11117-4 (https://pubmed.ncbi.nlm.nih.gov/39436412/)
● Filippi L, Ferrari C, Rubini G. Theranostic strategies in sarcoma: preliminary clinical evidence. Expert Opin Investig Drugs. 2024 Oct 9:1-9. doi: 10.1080/13543784.2024.2414119 (https://pubmed.ncbi.nlm.nih.gov/39367699/)
● Filippi L, Urso L, Ferrari C, et al. The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective. Eur J Nucl Med Mol Imaging. 2024 Aug 7. doi: 10.1007/s00259-024-06866-9. (https://pubmed.ncbi.nlm.nih.gov/39110196/)
● Filippi L, Urso L, Frantellizzi V, et al. Molecular imaging of PARP in cancer: state-of-the-art. Expert Rev Mol Diagn. 2023 Jul-Dec;23(12):1167-1174. doi: 10.1080/14737159.2023.2287503 (https://pubmed.ncbi.nlm.nih.gov/38009232/)
● Filippi L, Proietti I, Petrozza V, et al. The Prognostic Role of [18F]FDG PET/CT in Patients with Advanced Cutaneous Squamous Cell Carcinoma Submitted to Cemiplimab Immunotherapy: A Single-Center Retrospective Study. Cancer Biother Radiopharm. 2024 Feb;39(1):46-54. doi: 10.1089/cbr.2023.0110 (https://pubmed.ncbi.nlm.nih.gov/37883658/)
Link SCOPUS profile: https://www.scopus.com/authid/detail.uri?authorId=571968778
|
Dipartimento di Biomedicina e Prevenzione
Facoltà di Medicine e Chirurgia Università di Roma Tor Vergata Indirizzo: Viale Montpellier, 1 – Roma (Studio D12) |
Direttore del Dipartimento Prof. Luigi Tonino Marsella Responsabile Amministrativo Avv. Ombretta Picchioni Content manager del sito Prof. Andrea Malizia |